#Canada #Shareholders #Toronto #MediPharm Labs #Proxy Materials

MediPharm Labs Prepares for Annual Shareholder Meeting

MediPharm Labs Corp. (TSX: LABS), a prominent name in the pharmaceutical industry focusing on precision-based cannabinoid products, has initiated preparations for its forthcoming Annual and Special Meeting of Shareholders set for June 16, 2025. A crucial step in this process was the filing of their Management Information Circular (MIC) and associated proxy materials, which are being made available to the shareholders via the SEDAR+ website. The company aims to equip stakeholders with essential information designed to guide their voting decisions.

In a letter addressed to shareholders, Chris Taves, Chair of the Board, emphasized the significance of this annual meeting, asserting that the outcomes could greatly impact shareholder value. Taves encourages shareholders to cast their votes utilizing the GREEN proxy or voting instruction card, backing the company's nominated Board of Directors.

Recent Performance and Strategic Vision

Reflecting on the company's progress, Taves reported that MediPharm achieved a remarkable 27% increase in net revenue year-over-year, highlighting a gross profit margin rise from 18% to 31% in the same period. Despite operating expenses being under control, the company continues to hone its strategy following the merger with VIVO Cannabis, which they acquired the previous year.

MediPharm's dedication to its mission is evident in its revenue growth, substantial cost-cutting, and enhancement of its financial standing. The company is now nearing a positive Adjusted EBITDA, a critical benchmark for future profitability. The commitment to organic growth is a testament to the board's belief in their go-forward strategy.

However, the approach has faced challenges, notably from a shareholder, Apollo Technology Capital Corp., which recently filed a dissident proxy circular proposing alternative candidates for the Board of Directors. Taves expressed serious concerns regarding the intentions and qualifications of Apollo's nominees, who have not articulated a clear strategy for MediPharm's future.

Business Transformation Initiatives

Under the leadership of CEO David Pidduck, who took the helm in April 2022, MediPharm has undergone significant restructuring aimed at realigning its operations with its core capabilities. The priority has shifted towards developing key business lines, particularly in cannabis extracts. In addition, the strategic acquisition of VIVO Cannabis in 2023 has opened new avenues for international revenue, including strong performances in Australia and Germany. This acquisition not only broadened their market reach but also doubled the company's revenues since 2022.

A major factor driving MediPharm’s success is the company's rigorous adherence to Good Manufacturing Practices (GMP), setting a high standard in the cannabis sector that has facilitated its international expansion. The diversified product portfolio — which spans flowers, oils, and specialty products — alongside a balanced mix across various sales channels, makes MediPharm a promising player in a competitive environment.

Governance and Shareholder Engagement

Taves reiterated the commitment of MediPharm's Board to maintaining strong governance standards, which he believes is vital for managing business risks and aligning with stakeholder interests. With an entirely independent Chair and key committees, the governance framework is designed to support the company's accountability and operational integrity.

The Board’s commitment to fostering diversity and good governance practices is reflected in their proposal for two new independent director candidates with significant experience in capital markets and the cannabis sector. In contrast, Taves highlighted concerns about the dissident shareholders' slate, contending that the nominees lack the necessary industry experience to effectively direct MediPharm's strategic vision.

To encourage active shareholder participation, the company has made voting assistance readily available through its strategic advisor, Sodali Co. Shareholders can access all relevant materials at MediPharm’s dedicated AGM website to make informed decisions leading up to the meeting.

Looking Ahead

As MediPharm Labs prepares for its annual meeting, it stands at a critical juncture, where shareholder engagement and strategic clarity will play pivotal roles in shaping its future. The management remains optimistic, asserting that their current strategies are well-positioned to foster sustainable growth and ultimately enhance shareholder value.

As a summary, shareholders are urged to participate actively in the meeting, ensuring their voices are heard during this decisive period for MediPharm Labs. The support for the management proposed candidates is crucial for preserving the progress achieved and continuing on the path of recovery and expansion.